

SCRI Trials and Trial Regimen Updates

The following updates were completed between Nov. 14 - Dec. 11, 2025. Sarah Cannon Research Institute now manages all SCRI/USOR trials and trial regimens.

For questions about these trials and regimens, please contact SCRiKMEMRedits@McKesson.com.

New Builds Completed

Study Number	Notes for New Build
25157	USOR 25157 GI 430 Phase 3 PF-08634404 or Bevacizumab + mFOLFOX6 Q28D - 16Oct2025
25034	USOR 25034 GU 276 Phase 2 Arm A AAA617 + ARPI Q42D - v00 24JAN2025 USOR 25034 GU 276 Phase 2 Arm A ARPI Q84D- v00 24JAN2025 USOR 25034 GU 276 Phase 2 Arm A Randomization ARPI - v00 24JAN2025 USOR 25034 GU 276 Phase 2 Arm B AAA617 Q42D - v00 24JAN2025
24256	USOR 24256 GYN 142 Phase 3 Arm A T-DXd + Bevacizumab Q21D - v3.0 04DEC2024 USOR 24256 GYN 142 Phase 3 Arm B Bevacizumab Q21D - v3.0 04DEC2024
24299	USOR 24299 GYN 143 Phase 2 Post-IDS Mirvetuximab soravtansine + Carboplatin +/- Bevacizumab Q21D - v3.0 25AUG2025 USOR 24299 GYN 143 Phase 2 Pre-IDS Mirvetuximab soravtansine + Carboplatin Q21D - v3.0 25AUG2025
24305	USOR 24305 LUN 601 Phase 3 Afatinib Q21D - v1.0 15MAY2025 USOR 24305 LUN 601 Phase 3 Firmonertinib Q21D - v1.0 15MAY2025 USOR 24305 LUN 601 Phase 3 Osimertinib Q21D - v1.0 15MAY2025
25091	USOR 25091 LUN 630 Phase 3 Arm A PF-08046054 Q21D - 28May2025 USOR 25091 LUN 630 Phase 3 Arm B Docetaxel Q21D - 28May2025
24168	USOR 24168 MM 152 Phase 3 Arm A Teclistamab + Lenalidomide Q28D v7.0 21JUN2024 USOR 24168 MM 152 Phase 3 Arm B Lenalidomide Q28D v7.0 21JUN2024 USOR 24168 MM 152 Phase 3 Arm C Teclistamab Q28D v7.0 21JUN2024
24209	USOR 24209 RM 1007 Phase 1a TOS-358 Q21D - v6.2 07MAY2025 USOR 24209 RM 1007 Phase 1b TOS-358 + Fulvestrant + CDK4/6i Q28D - v6.2 07MAY2025 USOR 24209 RM 1007 Phase 1b TOS-358 + Fulvestrant Q28D - v6.2 07MAY2025
RM 1307 MCCR	M 1307 Phase 1 AXN-2510 Q21D - v1.3 17OCT2025
24304	USOR 24304 RM 905 Phase 1 Part B JZP815 Q28D - 03AUG2024
25037	USOR 25037 RM 1000 Phase 2 TNG260 + Pembrolizumab Q21D - v3.0 07MAR2024

Study Number	Notes for New Build
24197	USOR 24197 CLL 61 Phase 2 Pirtobrutinib Q28D - 30MAY2025
25176	USOR 25176 GU 303 Phase 1b/2 Cohort A PF-08634404 Q21D - 17Sep2025 USOR 25176 GU 303 Phase 1b/2 Cohort B PF-08634404 + Ipilimumab Q21D - 17Sep2025 USOR 25176 GU 303 Phase 1b/2 Cohort C PF-08634404 + Axitinib Q21D - 17Sep2025
RM 1199 MCCR	RM 1199 Phase 1 Part A Rezatapopt + Repaglinide + Midazolam + Metformin + Rosuvastatin D1-24 - v1 18JUL2025 RM 1199 Phase 1 Part B Rezatapopt Q21D - v1 18JUL2025
24205	USOR 24205 LYM 248 Phase 2 Arm 1 Zilovertamab vedotin + R-CHP Q21D - 05JUN2025 USOR 24205 LYM 248 Phase 2 Arm 2 Polatuzumab vedotin + R-CHP Q21D - 05JUN2024

Updated Reference Information

Study Number	Updated Reference Information	Updated Drug Service Order Information	Updated Regimen Instructions	Other Changes
21498	Version 6.0; 25 Feb 2025	N/A	N/A	Update Drug; Instructions
23122	Version 3.0; 19 Sept 2025	N/A	Regimen Comments; Admin	Update Drug; Instructions, premedication
23328	Version 3.0; 18 July 2025	N/A	Regimen Comments; Admin, Prophylaxis	Update Drug; Instructions
24026	PM v4.0; 30 July 2025	N/A	N/A	Update drug; instructions
24208	PM v2.0; 03 November 2025	N/A	N/A	Update drug; admin/prep, instructions
24259	PM v3.0; 12 November 2025	N/A	N/A	Update drug; instructions
24299	PA v3.0; 25 Aug 2025	N/A	Regimen Comments; Prophylaxis	Added; Drug
24320	PM v3.0; 06 October 2025	N/A	N/A	Update Drug; Dose/Form

Study Number	Updated Reference Information	Updated Drug Service Order Information	Updated Regimen Instructions	Other Changes
25018	Version 4.0; 23 June 2025	N/A	Regimen Comments; admin, observation	Update drug; instructions, admin/prep
25109	PM v3.0; 20 October 2025	N/A	N/A	Update drug; admin/prep
RM 1307 MCCR	Version 1.3; 17 October 2025	N/A	Regimen Comments; Observation	N/A
24112	PA3: 14 Jun 2025	N/A	N/A	Update drug; instructions
24075	PM v5.0; 17 October 2025	N/A	N/A	Update drug; instructions
24153	Version 2.0, 29JAN2025	N/A	Regimen comments; Admin	Update Drug; premedication
23245	PM v1.0: 31 Oct 2025	N/A	N/A	Update drug; instructions
23240	PA v7.0; 15 July 2025	N/A	Regimen comments; prophylaxis	Update drug; instructions
24130	Need to reactivate Cohort 2 Arms 1 and 3 (currently only Cohort 2 Arm 2 is active per outdated memo) 12/5 Site error these regimens are no longer needed.	N/A	N/A	Update drug; admin/prep, premedication
24006	PM v2.0; 20 November 2025	N/A	N/A	Update drug; instructions
24130	PCL; 29 Sept 2025	N/A	N/A	Update drug; admin/prep, instructions
23294	Amendment 5, 04Mar2025	N/A	Regimen Comments; Prophylaxis	Update Drug; admin/prep, premedication

Study Number	Updated Reference Information	Updated Drug Service Order Information	Updated Regimen Instructions	Other Changes
22090	DIL; 09 April 2025 DIL; 08 July 2025 PA v5.0; 11 July 2025 DIL; 14 August 2025	N/A	Regimen comments; admin	Update Drug; dose/form, instructions, procurement